|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 320.00 USD | -2.49% |
|
-5.34% | -19.53% |
| 01-27 | Intellia gets FDA nod to resume one gene therapy trial after safety pause | RE |
| 01-20 | RBC Cuts Price Target on Alnylam Pharmaceuticals to $465 From $500, Keeps Outperform Rating | MT |
Chart: Technical Analysis
Technical analysis trends
| Short Term | Mid-Term | Long Term | |
|---|---|---|---|
| Trend | Bearish | Bearish | Neutral |
| Resistance | 370 | 391.17 | 481.67 |
| Spread/Res. | -13.51% | -18.19% | -33.56% |
| Spread/Supp. | +2.85% | +9.37% | +36.43% |
| Support | 311.12 | 292.58 | 234.56 |
MarketScreener's Technical Analysis Ratings
| Short Term Timing | |
|---|---|
| Middle Term Timing | |
| Long Term Timing | |
| RSI | |
| Bollinger Spread | |
| Unusual Volumes |
- Stock Market
- Equities
- ALNY Stock
- Charts Alnylam Pharmaceuticals, Inc.
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition